Biomm

Biomm FCF Yield

The Free Cash Flow Yield of Biomm (BIOM3.SA) as of Nov 11, 2026 is -16.51 %. In the previous year, Free Cash Flow Yield was -13.23 % — a change of 24.77% (lower).

FCF Yield

-16.51 %

YoY

24.77%

Last updated:

Free Cash Flow Yield of Biomm is 2025 -16.51 % . Free Cash Flow Yield of Biomm was 2024 -13.23 % . It decreases by 24.77% lower compared to the previous year.

The Biomm FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-5.37 BRL
Jan 1, 2019
-10.13 BRL
Jan 1, 2020
-12.10 BRL
Jan 1, 2021
-12.07 BRL
Jan 1, 2022
-8.16 BRL
Jan 1, 2023
-9.66 BRL
Jan 1, 2024
-13.23 BRL
Jan 1, 2025
-16.51 BRL
The Biomm FCF Yield history
YEARFCF YieldYoY
-16.51 %+24.77%
-13.23 %+37.03%
-9.66 %+18.37%
-8.16 %-32.39%
-12.07 %-0.27%
-12.10 %+19.47%
-10.13 %+88.69%
-5.37 %-25.22%
-7.18 %-40.64%
-12.09 %+110.39%
-5.75 %+11.28%
-5.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

Free Cash Flow Yield of Biomm is -16.51 % in 2025.

Free Cash Flow Yield of Biomm changed from -13.23 % to -16.51 %, representing a 24.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Biomm since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Biomm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biomm

All Key Metrics — Biomm